Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives
- Why talk about IBD?
- Increasing incidence & prevalence of IBD
- IBD in the young
- The changing “face” of IBD
- The heavier you are, the worse you do
- The history: Systemic complications
- EIMs in IBD: Overall prevalence
- Not everything is Crohn’s: Small bowel mimics
- Right sided colonic thickening: Crohn’s?
- Therapeutic pyramid
- Site of oral mesalamine release
- Comedications in IBD
- Laboratory testing: Medication dependent
- Anti-TNF agents: Adverse events
- Anti-TNF: Side effect profile
- “Can I stop my medicine?”
- Predictors of rapid progression to surgery
- Factors of poor outcome in UC
- Role of patient perception
- CAM and IBD
- Herbal supplements
- Vitamin D and disease activity
- Cannabis usage in CD
- Vaccines
- Live vaccinations
- Pneumococcal vaccination in IBD patients on immune suppressants
- Depression
- Risks of dysplasia or CRC in UC
- Summary
- Disclosure of financial relationships
Topics Covered
- Clinical epidemiology and characteristics of IBD
- Diagnostic testing
- Medical treatment of UC and CD
- Adverse events with medications
- Assessing extraintestinal manifestations of IBD
- Complications of disease
- Alternative Therapies for IBD
- Vaccination advice
- Mental health issues
- Cancer screening
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kane, S. (2021, May 30). IBD for the non-gastroenterologist [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VYEA4824.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sunanda Kane, Consultant: Abbot, Elam, Shire, UCB / Grant/Research Support (Principal Investigator): Elam, Shire.
A selection of talks on Gastroenterology & Nephrology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I am Dr. Sunanda Kane,
professor of medicine and gastroenterologist at Mayo Clinic in Rochester,
Minnesota in the United States.
Today we're going to talk about inflammatory bowel
disease (IBD) for the non-gastroenterologist.
0:17
Today, our learning objectives include: understanding the changing epidemiology of IBD;
recognizing some common mimics, of Crohn's disease in particular;
appreciating the therapeutic monitoring for IBD;
and being comfortable with non-therapeutic management issues in the IBD patient.
0:38
Why should we talk about IBD at all for the non-gastroenterologist?
It's very interesting that there was a nice epidemiologic study done looking
at the care of IBD patients from 1998 through 2005.
During this time, there was a 450 percent increase in visits to
primary care physicians by Crohn's patients, and
350 percent by ulcerative colitis patients.
The decrease in Crohn's disease patients for 5-ASA use was seven percent,
steroid use was decreased by 36 percent in Crohn's and 27 percent in ulcerative colitis.
The good news here was a decrease in hospitalizations by
33 percent in Crohn's patients and almost the same in ulcerative colitis,
then the decrease in surgery didn't change for Crohn's,
but there was a 50 percent decrease in surgery rates for ulcerative colitis over
this timeframe when there was a parallel in increased visits to primary care physicians.
Clearly, there is a signal here that primary care is as important as,
if not more important
than, the care from a gastroenterologist in terms of outcomes and treatment.